(Reuters) -The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

Regeneron remains committed to supporting patient access to medications and believes that patients should be able to access whatever therapy their physician prescribes for them.

Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on ...

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to acquire 23andMe, the genetic testing ...

The latest international Regeneron Pharmaceuticals Inc news and views from Reuters - one of the world's largest news agencies ...

Regeneron has asserted the ’865 patent in BPCIA litigations against Mylan, Samsung Bioepis, Celltrion, Formycon, and Amgen.